Here's a rapid-fire update on all stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Jim ran through each stock Wednesday during our October Monthly Meeting. Apple : Our "own it, don't trade it" mantra on Apple has served us well over the years, and there's been no change to that approach amid the stock's up-and-down ride since August.
Eli Lilly : After a multiweek slide in September, Eli Lilly has returned to its winning ways and is on track to close at a fresh all-time high Wednesday amid additional optimism around the medical benefits that drugs in the GLP-1 category could deliver. Lilly's diabetes drug Mounjaro, which may soon be approved to also treat obesity, is in the GLP-1 class. More generally, we're pleased with the manufacturing investments Lilly has been making.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: CNBC - 🏆 12. / 72 اقرأ أكثر »